Search trials – HealthDB

Активни: Recruiting ×

Намерени 4,436 изпитвания Стр. 159 от 222

Recruiting

Post-Market Clinical Follow Up for Total Knee Arthroplasty System Madison

Knee Arthropathy

MADISON Total Knee Prosthesis is intended to be used for total knee arthroplasty to reduce pain and restore joint mobility of the knee. Clinical data for MADISON Total Knee Prosthesis available are not deemed sufficient to support performance and benefits claimed on the whole lifetime of the product. Thus, in order to maintain compliance with the EU regulation (2017/745) related to medical devices and following ISO 14/155:2020, SERF has set up post-market clinical follow-up study (PMCF) to confirm safety and performance of Total Knee Arthroplasty system MADISON. This study is designed to cover the expected 15-years follow-up, to retrieve data according to implant feature (Posterior Stabilized or Ultra Congruent) or fixation method and to gather data related to the revision of partial knee prosthesis. The primary objective of this study is to assess the clinical safety of MADISON total knee prostheses. The secondary objective is to evaluate the survival rates, the clinical performances and clinical benefits of MADISON total knee prosthesis.

Начало: 17.10.2023 Край: 31.12.2040 Възраст: от 18 г.

France Societe dEtude, de Recherche et de Fabrication NCT06120023

Recruiting Phase 1

A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants

Healthy

This is a sequential, randomized, double-blind, placebo-controlled Phase 1 single (SAD) and multiple (MAD) ascending dose study to evaluate the safety, tolerability, and pharmacokinetics (PK) of orally or intravenously administered LTG-001 in healthy male and female participants

Начало: 17.10.2023 Край: 28.04.2026 Възраст: 18–55 г. Treatment

New Zealand Latigo Biotherapeutics NCT06049095

Recruiting

The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease

Aortoiliac Occlusive Disease Peripheral Arterial Disease

The objective of this prospective, multicenter, randomized, controlled clinical trial is to demonstrate the superiority of the VBX Device for primary patency when compared to bare metal stenting in complex iliac occlusive disease.

Начало: 17.10.2023 Край: 31.01.2032 Възраст: от 18 г. Treatment

Germany, Netherlands, New Zealand +1 W.L.Gore & Associates NCT05811364

Recruiting

Ablative Radiotherapy to Restrain Every Metastasis Safely Treatable (ARREST-2): A Randomized Phase II/III Trial

Metastatic Cancer

This is a phase II/III international multicentre randomized trial. Patients will be randomized in a 1:2 ratio between the standard of care (Arm 1) and SABR (Arm 2) to all sites of disease. The study will start as a phase II trial with an opportunity to convert to a phase III trial. The objective of this trial is to determine the impact of SABR on overall survival, progression-free survival, quality of life, and toxicity in patients with polymetastatic disease.

Начало: 16.10.2023 Край: 01.01.2034 Възраст: от 18 г.

Canada, Switzerland London Health Sciences Centre Research Institute OR Law NCT05508464

Recruiting

Identification of Therapeutic Targets in Metastatic Gastric Cancer

Stomach Neoplasms, Benign

This is a pilot study aiming at identifying novel therapeutic molecular targets in patients with gastric cancer with lymph nodes or distant metastasis. All patients who are diagnosed with gastric cancer with metastases in the Prince of Wales Hospital will be screened for eligibility.

Начало: 15.10.2023 Край: 01.10.2033 Възраст: 18–80 г.

Hong Kong Chinese University of Hong Kong NCT07551440

Recruiting Phase 1

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

Triple Negative Breast Cancer Diffuse Large B Cell Lymphoma Follicular Lymphoma Lymphoma, Non-Hodgkin +10

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.

Начало: 13.10.2023 Край: 29.08.2026 Възраст: от 18 г. Treatment

Australia, United States OncoNano Medicine, Inc. NCT06022029

Recruiting

Clinical Trial of Blenderized Tube Feeds Varying in Viscosity

Feeding Disorders

The investigators are conducting a 16 week multiple cross-over study (N-of-1 trial) comparing two blenderized tube feeds varying in viscosity in 40 children.

Начало: 12.10.2023 Край: 01.04.2028 Възраст: от 1 г.

United States Boston Children's Hospital NCT05417958

Recruiting Phase 1

A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors

Advanced / Metastatic Solid Tumor

This is an open-label, dose-escalation, multi-center phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of SR-8541A administered orally as a monotherapy or in combination with an immune checkpoint inhibitor (ICI) in subjects with solid tumors.

Начало: 12.10.2023 Край: 01.12.2025 Възраст: от 18 г. Treatment

Australia Stingray Therapeutics NCT06063681

Recruiting Phase 2

A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.

Mantle Cell Lymphoma Mantle Cell Lymphoma Refractory

The goal of this clinical trial is to evaluate the safety and response of combining Pirtobrutinib and Glofitimab in patients with relapsed MCL. The main question it aims to answer are: * Will additive and synergistic effects be observed when using a combination of glofitamab and pirtobrutinib? * Will this combination be safe and lead to high complete- and remission rates with no residual disease? Pirtobrutinib will be given to all participants as an oral tablet for the duration of the entire study. Participants will receive other treatment in 3 phases: 1. Treatment Ramp-Up 1. Treatment with Obinutuzumab by Intravenous (IV) 2. An initial dose level of Glofitamab will evaluate step-up dosing. If excessive adverse events are observed, a lower initial dose will be used. 2. Fixed course combination phase: Treatment with Glofitamab by IV 3. Maintenance phase: Glofitamab is discontinued. 200mg oral daily

Начало: 12.10.2023 Край: 01.04.2037 Възраст: от 18 г. Treatment

Australia Australasian Leukaemia and Lymphoma Group NCT05833763

Recruiting

PRostate Olaparib Real World Evidence Study

Metastatic Castration-resistant Prostate Cancer

This French non-interventional longitudinal multicenter cohort study is conducted to study the added value of olaparib in the treatment of patients with mCRPC in the real world setting in terms of treatment sequencing, effectiveness, safety and BRCA testing patterns and thus inform future clinical practice.

Начало: 11.10.2023 Край: 13.10.2028 Възраст: от 18 г.

France AstraZeneca NCT06031805

Recruiting Phase 3

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Alopecia Areata

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body. The purpose of this study is to assess how safe, effective, and tolerable upadacitinib is in adolescent and adult participants with severe AA. Upadacitinib is an approved drug being investigated for the treatment of AA. In Study 1 and Study 2 and Study 4 Period A, participants are placed in 1 of 3 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 5 chance that participants will be assigned to placebo. In Study 1 and Study 2 and Study 4 Period B, participants originally randomized to upadacitinib dose group in Period A will continue their same treatment in Period B. Participants originally randomized to Placebo in Period A will either remain on placebo in Period B, or be randomized in 1 of 2 groups, based off of their Severity of Alopecia Tool (SALT) score. Participants who complete Study 1, Study 2 or Study 4, can join Study 3 and may be re-randomized to receive 1 of 2 doses of upadacitinib for up to 108 weeks. Around 1500 participants with severe AA will be enrolled in the study at approximately 280 sites worldwide. Participants will receive oral tablets of either upadacitinib or placebo once daily for up to 160 weeks with the potential of being re-randomized into a different treatment group at Weeks 24 and 52. Participants will be followed up for up to 30 days after last study drug dose. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Начало: 11.10.2023 Край: 01.04.2030 Възраст: 12–63 г. Treatment

Argentina, Australia, Belgium +24 AbbVie NCT06012240

Recruiting Phase 3

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

Community-acquired Pneumonia

This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with community acquired pneumonia (CAP).

Начало: 10.10.2023 Край: 31.03.2029 Възраст: от 18 г.

Brazil, Canada, United States University of Manitoba NCT05848713

Recruiting Phase 3

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

Lung Transplant Rejection

This double-blind, randomized, placebo-controlled, multinational, multicenter, parallel-group, Phase 3, 2-arm, study will investigate the efficacy and safety of belumosudil compared with placebo, both administered on top of azithromycin and standard-of-care regimen of immunosuppression in male or female participants at least 1 year after bilateral lung transplant, who are at least 18 years of age and who have evidence of progressive CLAD despite azithromycin therapy. Study details include: The study duration will be up to 31 weeks for participants not entering the open-label extension (OLE) period and up to 57 weeks for participants entering the OLE period but not the long-term OLE. The treatment duration will be up to 26 weeks for participants not entering the OLE period and up to 52 weeks for participants entering the OLE period but not the long-term OLE. The number of visits will be up to 10 visits for participants not entering the OLE period and up to 16 visits for participants entering the OLE period but not the long-term OLE. For participants who enter the long-term OLE, treatment and study participation will continue with visits every 12 weeks per protocol specifications.

Начало: 10.10.2023 Край: 01.10.2030 Възраст: от 18 г. Treatment

Australia, Belgium, Canada +16 Sanofi NCT06082037

Recruiting

SEAL™ME: Saccular Endovascular Aneurysm Lattice System Multicenter Enrollment Global Registry

Aneurysm Aneurysm, Ruptured

Prospective, international, single-arm, multicenter, registry study. Patients presenting with evidence of Wide Neck unruptured or ruptured intracranial aneurysm (≤ 20 mm in widest diameter) requiring treatment will be enrolled into the study and treated using the SEAL™ System.

Начало: 09.10.2023 Край: 15.06.2030 Възраст: 18–80 г.

Colombia, New Zealand, Pakistan +1 Galaxy Therapeutics INC NCT05880680

Recruiting Phase 1

HNC: Human Neural Circuits Electrophysiology During Cognition

Psychiatric Disorder

The purpose of this study is to understand how ketamine brings about dissociative symptoms.

Начало: 05.10.2023 Край: 01.09.2030 Възраст: от 18 г.

United States Stanford University NCT05962424

Recruiting Phase 3

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Breast Cancer, Early Breast Cancer

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.

Начало: 05.10.2023 Край: 06.05.2037 Възраст: 18–130 г. Treatment

Argentina, Australia, Belgium +39 AstraZeneca NCT05952557

Recruiting Phase 4

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Multiple Myeloma

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

Начало: 03.10.2023 Край: 22.02.2032 Възраст: от 18 г. Treatment

Australia, Canada, China +3 Pfizer NCT06057402

Recruiting

Indirect Calorimetry Guided Energy Provision in Critically Ill Patients With Obesity

Critical Illness Obesity

The DIRECT trial is a prospective, multi-centre, two arm parallel feasibility pilot randomised controlled trial. The primary aim is to determine the feasibility of using repeat indirect calorimetry measurements to direct energy delivery in critically ill patients with obesity. The trial will recruit 60 mechanically ventilated patients from 4-6 ICUs in Australia and New Zealand.

Начало: 02.10.2023 Край: 01.06.2026 Възраст: от 18 г. Other

Australia, New Zealand Australian and New Zealand Intensive Care Research Cent NCT06053216

Recruiting

Evaluation of the NaviFUS System in Drug Resistant Epilepsy

Epilepsy, Temporal Lobe Drug Resistant Epilepsy

Participants with drug-resistant epilepsy (DRE) enrolled in this study will receive focused ultrasound (FUS) treatment with the NaviFUS System, guided by the neuronavigation system to evaluate the safety and efficacy of using NaviFUS System. During the treatment, the FUS will electronically scan and target to the assigned zones on one or both of the hippocampi. The study consists of a 60-day screening period for baseline observation prior to treatment, a FUS treatment period of 2 weeks for Cohort 1 or 3 weeks for Cohort 2 with 2 FUS treatments per week using the NaviFUS System, and a safety follow-up period of 81 days.

Начало: 02.10.2023 Край: 01.07.2026 Възраст: от 18 г. Treatment

Australia Genovate-NaviFUS (Australia) Pty Ltd. NCT05947656

Recruiting Phase 3

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis (JIA) is the most common type of arthritis that affects children. The term "idiopathic" means "of unknown origin". It is a chronic (long-lasting) disease that causes swelling, warmth, and pain of one or more small joints. Systemic JIA ia a rare and serious form of JIA. Systemic" means it may affect not only the joints but other parts of the body, including the liver, lungs and heart. sJIA is more severe and can be more challenging to diagnose and treat than other types of juvenile idiopathic arthritis. It is a lifelong disease for many patients and can continue into adulthood. This study will assess how safe and effective upadacitinib is in treating pediatric and adolescent participants aged 1 to \< 18 with systemic juvenile idiopathic arthritis (sJIA) and will include a tocilizumab treatment arm for reference. Adverse events and change in the disease activity will be assessed. Upadacitinib is an investigational drug being developed for the treatment of sJIA. Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive upadacitinib or tocilizumab reference. In cohort 2, participants will receive upadacitinib. Approximately 90 participants with sJIA will be enrolled in approximately 45 sites worldwide. Participants will receive upadacitinib oral tablets once daily or oral solution twice daily or tocilizumab subcutaneous injection or intravenous infusion as per local label for 52 weeks and followed for approximately 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits/calls during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

Начало: 02.10.2023 Край: 01.06.2029 Възраст: 1–17 г. Treatment

Argentina, Australia, Brazil +13 AbbVie NCT05609630

1 … 157 158 159 160 161 … 222